- AU$845.92m
- AU$713.83m
- AU$203.89m
Australia's Nanosonics hits 2-year low on forecast miss
Brief: Nanosonics Posts FY Net Income Attributable Of AUD 17.8 Million
Australia's Nanosonics set for worst day in over two months on weak interim profit
Morningstar sees Nanosonics' endoscope-cleaning device supporting recurring revenue
Brief: Nanosonics To Commence A$20 Million Share Buy-Back Program
Australia's Nanosonics rises on higher annual profit
Brief: Nanosonics Posts FY Revenue AUD 198.6 Million
Brief: Nanosonics Posts FY Gross Margin 78.2%
Brief: Nanosonics Receives US FDA Clearance For Next Generation Trophon Technology
Australia's Nanosonics rises on U.S. FDA clearance for disinfection product
Morningstar maintains fair value estimates on Aussie health firms despite Trump's 200% tariffs plan
Bell Potter downgrades Australia's Nanosonics on US tariff impact; stock down
Australian healthcare stocks rise as Bell Potter sees most cos unfazed by potential tariffs
Brief: Nanosonics Receives FDA De Novo Clearance For Coris
Australia's Nanosonics gains on FDA's De Novo clearance for CORIS system
Brief: Nanosonics Ltd Says It Expects FY Revenue Growth Of 11% - 14%
Australia's Nanosonics climbs to two-year high on upbeat HY results
Brief: Nanosonics Anticipates Total Revenue For Half To Be A$93.6 Million
Australia's Nanosonics climbs on FY results beating consensus